The study found that patients with Covid-19 treated in hospital who “received ivermectin early reported substantial recovery” and that there was “a substantial improvement and reduction in mortality rate in ivermectin treated groups” by 90%.
But the drug’s promise as a treatment for the virus is in serious doubt after the Elgazzar study was pulled from the Research Square website on Thursday “due to ethical concerns”. Research Square did not outline what those concerns were.
A medical student in London, Jack Lawrence, was among the first to identify serious concerns about the paper, leading to the retraction. He first became aware of the Elgazzar preprint when it was assigned to him by one of his lecturers for an assignment that formed part of his master’s degree …